KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 0.4.

  • Emergent BioSolutions' Equity Ratio rose 1589.26% to 0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4, marking a year-over-year increase of 1589.26%. This contributed to the annual value of 0.35 for FY2024, which is 244.82% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Equity Ratio of 0.4 as of Q3 2025, which was up 1589.26% from 0.38 recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Equity Ratio registered a high of 0.57 during Q1 2022, and its lowest value of 0.26 during Q2 2024.
  • Its 5-year average for Equity Ratio is 0.43, with a median of 0.41 in 2023.
  • In the last 5 years, Emergent BioSolutions' Equity Ratio tumbled by 4193.29% in 2024 and then skyrocketed by 4824.64% in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Equity Ratio stood at 0.54 in 2021, then decreased by 19.56% to 0.44 in 2022, then decreased by 18.74% to 0.36 in 2023, then dropped by 2.45% to 0.35 in 2024, then increased by 14.76% to 0.4 in 2025.
  • Its Equity Ratio was 0.4 in Q3 2025, compared to 0.38 in Q2 2025 and 0.39 in Q1 2025.